LAAOS III: Surgical LAA Closure Cuts AF Stroke Risk by One Third medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Credit: Hamilton Health Sciences
Hamilton, ON (May 15, 2021) - A simple surgery saves patients with heart arrhythmia from often-lethal strokes, says a large international study led by McMaster University.
Researchers found that removing the left atrial appendage an unused, finger-like tissue that can trap blood in the heart chamber and increase the risk of clots cuts the risk of strokes by more than one-third in patients with atrial fibrillation.
Even better, the reduced clotting risk comes on top of any other benefits conferred by blood-thinner medications patients with this condition are usually prescribed. If you have atrial fibrillation and are undergoing heart surgery, the surgeon should be removing your left atrial appendage, because it is a set-up for forming clots. Our trial has shown this to be both safe and effective for stroke prevention, said Richard Whitlock, first author of the study.
Share:
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels
Amarin to Webcast Discussion of Data Presented at ACC.21 Monday, May 17, 2021 at 4:30 p.m., Eastern Time
DUBLIN, Ireland and BRIDGEWATER, N.J., May 15, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT
® HEART FAILURE (HF) at ACC.21, the American College of Cardiology s 70th Annual Scientific Session, being held virtually from May 15 – 17, 2021. These new analyses supported by Amarin were presented on behalf of all authors by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women s Hospital, Harvard Medical School, Boston, MA.
received a breakthrough designation
from the FDA. (Edwards)
Altogether, 98% of those participants saw the acuteness of their regurgitation downgraded from previously “torrential,” “massive” or “severe” categories, and on average were able to walk 50 meters farther during a six-minute walking test.
Two deaths were reported, with one linked to cardiovascular disease, in addition to 12 cases of severe bleeding, none of which were life-threatening or fatal according to the trial’s investigators; 77% of patients had no major side effects after 30 days.
The study, named Triscend, will follow up with its participants at 6 months and annually for at least five years. Based on its positive results, Edwards recently began treating patients with Evoque in Triscend II, an open-label pivotal trial that aims to enroll at least 775 participants through 2024.